Background: Allergic eye diseases influences around one-fifth of the total populace. Olopatadine hydrochloride and Azelastine hydrochloride are double acting selective H1 receptor antagonist with mast-cell stabilizing property. This investigation was embraced to evaluate the adequacy and wellbeing of olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% in allergic conjunctivitis. Materials and Methods: 80 patients with the sign (hyperemia) and side effects of allergic conjunctivitis (i.e., tearing, itching and photophobia) were randomized (stratifying by age and sex) 1:1 to get either 0.1% with olopatadine hydrochloride (OHCL) and Azelastine 0.05% eye drops BD for 15 days (one drop in each eye each 12 h). Signs and manifestations were scored prior and then afterward 2 weeks of medication while side effects were scored 30 min and 2 weeks after treatment start. A composite score of signs and indications was characterized by including all measures of signs and manifestations and after that subtracting the week 2 entirety from the pretreatment aggregate. Result: Both medications decreased signs and indications of allergic conjunctivitis at 2 weeks from gauge. The treatment with 0.1% OHCL was more powerful contrasted with the azelastine gathering. Essentially, the scores of ocular congestion, foreign body sensation, tearing, erythema and chemosis likewise demonstrated bigger decrease in the olopatadine treated patients. Conclusion: The aftereffects of this single-dosage contemplate recommend that olopatadine is better than epinastine regarding smothering ocular itching and hyperemia. Additionally contemplates are expected to affirm these discoveries, in real-life settings.
Keywords: Olopatadine hydrochloride(OHCL), Allergic conjunctivitis (AC), Hyperaemia.
Corresponding author: Dr. Anil Sinha, Professor, Department of Pharmacology, Government Medical College, Betiah, Bihar, India
This article may be cited as: Barkat S, Sinha A. Efficacy and safety of Olopatadine versus Azelastine in allergic conjunctivitis at a Government Medical College, Betiah, Bihar- A prospective study. J Adv Med Dent Scie Res 2017;5(8):47-51.